CD274 and non-small cell lung carcinoma: In comparison, in the recent five-year updates of the KEYNOTE-189 and -407 studies comparing chemo-immunotherapy with standard chemotherapy among patients with nonsquamous and squamous NSCLC, the proportion of patients completing 2 years of treatment in the PD-L1 greater than or equal to 50% was 23.4% and 21.9%, respectively.15